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Objectives: The health and economic burden of Hepatitis C virus (HCV) infection 
in chronic kidney disease (CKD) patients in the United States is significant. GZR 
(NS3/4A protease inhibitor)/EBR (NS5A inhibitor) have been shown to be highly effec-
tive and well tolerated in HCV G1 patients with advanced CKD. Our objective was to 
project the clinical and economic impact of GZR/EBR compared with no treatment 
(NoTx) and pegylated interferon plus ribavirin (peg-IFN/RBV). MethOds: A state-
transition model of chronic HCV, liver disease, and CKD was developed to project 
lifetime incidence of liver complications, including hepatocellular carcinoma (HCC), 
life expectancy, discounted quality-adjusted life years (QALY), and discounted dis-
ease cost (COST) (2015 US dollars). Efficacy of GZR/EBR was obtained from C-SURFER, 
a phase 2/3, randomized, double-blind, placebo-controlled trial of GZR/EBR in HCV 
G1 patients in CKD stages 4/5. In the pre-specified primary population, the propor-
tion of patients achieving sustained viral response 12 weeks after the completion 
of therapy was 0.99 (0.95–1.00). Based on the results of a meta-analysis, we assumed 
an efficacy of 0.60 (0.47–0.71) for peg-IFN/RBV. Data on baseline characteristics of the 
simulated patients were obtained from NHANES. Natural history parameters were 
estimated from published studies. Drawing parameter values from well-defined 
statistical distributions, one-thousand Monte Carlo simulations were conducted 
to estimate mean incidence and 95% uncertainty intervals. Results: Incidence of 
HCC was 1.11% (0.05–4.61) with GZR/EBR compared with 23.20% (8.79–42.30) when 
NoTx was used and 9.83% (2.85–21.26) with peg-IFN/RBV. Compared with NoTx 
and peg-IFN/RBV, GZR/EBR increased QALYs by 2.38 (1.62–3.30) and 1.41 (0.76–2.22) 
years, respectively. COST of $138,304 (122,047–155,296) was lowest with GZR/EBR. 
In comparison, Peg-IFN/RBV’s COST was $144,562 (126,553–165,999) and COST with 
NoTx was $162,846 (141,624–187,487). cOnclusiOns: Our model predicts that GZR/
EBR will reduce the incidence of liver-related complications and disease costs and 
prolong QALYs in patients with HCV G1 infection and CKD.
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Objectives: To explore the cost-effectiveness of bacterial whole-genome sequenc-
ing (bWGS) in determining antibiotic resistance and selecting antibiotics for treat-
ment of urinary-tract infections (UTI), from the perspective of the UK National 
Health Service. MethOds: A decision-tree model was developed to compare the 
cost-effectiveness of UTI treatment with or without bWGS. Nitrofurantoin (NTF), tri-
methoprim and co-amoxiclav were designated as first-, second- and last-line treat-
ments respectively, in accordance with treatment guidelines. Parameters extracted 
from peer-reviewed literature included the prevalence of resistance and disease-state 
utilities. Duration and cost of treatments were taken from the British National 
Formulary. The cost and time to perform bWGS for a complete E. coli genome using 
the MiSeq platform were estimated. The incremental cost-effectiveness ratio was 
calculated as cost (GBP) per quality-adjusted life-year (QALY). Threshold analyses 
were performed to explore scenarios where bWGS could become a cost-effective 
strategy. Results: Using a current prevalence of resistance to NTF of 5.3% and a cost 
per genome of £39.69, bWGS was dominated; being more expensive and with worse 
health outcomes than current clinical practice. However, an ~80% reduction in cost 
of sequencing would lead to bWGS being cost-saving compared to current practice. 
Alternatively, if NTF resistance prevalence increased to 44%, bWGS could become cost-
effective at £20,000/QALY. Under some scenarios, such as a reduced bWGS cost of £15 
per genome and increased NTF resistance prevalence of 25%, bWGS would become 
a dominant strategy; being less expensive with better health outcomes than current 
practice. cOnclusiOns: Currently bWGS is not likely to be a cost-effective option for 
directing the selection of antibiotics in the treatment of UTIs; however, in the probable 
situation that the cost of sequencing decreases and resistance to first line antibiot-
ics increases, bWGS is expected to become a cost-effective or dominant option. This 
technology therefore has great potential for improving antibiotic stewardship.
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Objectives: To assess the cost-effectiveness of mirabegron compared with anti-
muscarinic agents: tolterodine, solifenacin and fesoterodine, in patients with 
overactive bladder (OAB) symptoms from a Spanish National Health Service (NHS) 
perspective. MethOds: A Markov model was developed to simulate the course and 
disease management, as well as the adverse effects of treatment, in OAB patients 
over a period of 5 years. Direct health care costs (€ , cost year 2015) included drug 
acquisition, primary care physician and specialist physician visits, incontinence 
pads, surgical procedures, adverse effects of treatment and botox injectionswere 
obtained from Spanish sources. Relative effectiveness estimates of mirabegron 
50mg vs tolterodine , fesoterodine, solifenacin 5 and 10mg were obtained from a 
network meta-analysis, using a calibration method. Effectiveness was measured as 
quality-adjusted life-years (QALYs) gained. Other model inputs were derived from 
the literature or clinical expert opinion. Deterministic and probabilistic sensitivity 
analyses (SA) were undertaken. Results: Mirabegron 50mg/day was associated 
with a gain of 0.01259 QALYs at an additional cost of € 194 per patient vs tolterodine 
Objectives: To carry out a cost and consequences analysis (CCA) of treating 
Overactive Bladder (OAB) with two flexible-dose of Fesoterodine in routine medi-
cal practice in Spain, from the perspective of the Spanish National Health System 
(NHS). MethOds: The CCA was populated with data from an observational, ret-
rospective and multicenter study including OAB patients, both genders, aged 18+ 
years-old managed under routine medical practice conditions of care. OAB patients 
initiating flexible-dose of Fesoterodine were included in two groups according with 
the flexible posology prescribed: escalating from 4-to-8mg (escalating group) or 
initiating and maintaining 8mg (maintaining group). Consequences included a 
health outcomes profile from the patient perspective and the clinician judgment. 
Costs were estimated from healthcare resources utilization only and used year 
2015 unitary prices. The patient outcomes measures included symptoms severity 
and specific quality-of-life by using the OAB-q questionnaire, Patient Perception 
Bladder Condition (PPBC), Patient Perception Urgency Scale (PPUS), and Treatment 
Benefit Scale (TBS). Clinician judgment was approached by the Clinical Global 
Impression (CGI) scale. General linear models, logistic and ordinal regression 
adjusting by covariates were applied. Results: A total of 350 (156 in maintain-
ing group and 194 in escalating) symptomatic OAB patients were extracted from 
the study to populate the CCA. Adjusted healthcare total costs were not statisti-
cally different; € 50.6 (CI:157.4-55.1), p= 0.361. However, patient-reported-outcomes 
were significantly better in the maintaining group than in the escalating; OAB-q 
symptoms (22.6 vs. 26.8, p= 0.015), HRQoL (74.5 vs. 71.1, p= 0.053), less patients 
with urinary incontinence (29.5% vs. 46.4%, OR= 0.4 (CI:0.3-0.7), p= 0.001, and bet-
ter perception or urgency OR= 1.8 (CI:1.2-2.8), p= 0.008. cOnclusiOns: Despite 
the study design, this cost-consequences analysis found that initiating 8mg dose 
of fesoterodine was associated with similar healthcare costs but better patient 
outcomes than escalating from 4mg in the treatment of Overactive Bladder in 
routine medical practice.
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Objectives: The use of low-osmolar contrast media has reduced the frequency of 
Contrast-Induced Nephropathy (CIN), however, it still exists. As no data are avail-
able in France, a study was set up to estimate the hospital burden associated to this 
complication in terms of medical resource used and hospital costs. MethOds: 
A retrospective, observational study was conducted using the French exhaustive 
hospital discharge database (PMSI). Stays with an interventional radiology or car-
diology procedure involving the use of a contrast media were identified in 2012 and 
2013 in adults. CIN was defined as the occurrence over the stay of a nephropathy 
CIM-10 code or unscheduled dialysis procedure. Patients’ characteristics and stays 
were described, as well as associated costs. Results: In 2012 and 2013, 1,047,329 
stays were identified with an interventional procedure. Patients were mainly men 
(68.0%) with a mean age of 66.1±13.8. Among those patients, 25.8% were diabetics, 
9.2% had Chronic Kidney Disease (CKD), 3.4% were suffering from heart failure 
and 0.2% had a cardiogenic shock. Overall CIN rate was 3.1%. CIN resulted in an 
extra length of stay (LOS) of 15.8 days (20.5 vs 4.7 days, p< 0.0001) and an extra cost 
of € 12,413 (€ 15,765 vs€ 3,352, p< 0.0001). This result was very similar in each sub-
group analysis (extra cost of € 11,030 for diabetics, € 11,437 for CKD and € 7,257 for 
patients with heart failure). In France, the hospital cost of CIN reached a total cost 
€ 401,023,050 in 2012 and 2013, making it € 200,511,525 per year. cOnclusiOns: 
This study shows that CIN was associated with significant hospital costs due 
to increased LOS, even more when dialysis occurred. The hospital cost of CIN 
could partially cut down through better preventing measures including safer 
media use.
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Objectives: To assess the cost-effectiveness of a fixed-dose combination (FDC) 
of solifenacin 6 mg/day plus an oral controlled absorption system formulation of 
tamsulosin (TOCAS 0.4 mg/day) compared to tolterodine ER 4 mg/day concomi-
tantly given with tamsulosin 0.4 mg/day in men with lower urinary tract symptoms 
(LUTS) associated with benign prostatic hyperplasia (BPH) in Spain. MethOds: A 
Markov model with a 4-week cycle period was developed for men aged ≥ 45 years 
with LUTS/BPH who have moderate-to-severe storage and voiding symptoms. The 
model estimated cost effectiveness over an analytical time horizon of 1 year from 
the perspective of the Spanish National Health System (NHS). Direct health care 
costs (drug acquisition, primary care physician visits and surgical procedures) 
were considered. The effectiveness of treatments was measured using quality-
adjusted life-years (QALYs) gained. Utility values were derived from EQ-5D data 
collected in a randomized controlled trial. Other model inputs were derived from 
the literature or clinical expert opinion. Deterministic and probabilistic sensitivity 
analyses (SA) were undertaken. Results: The FDC of solifenacin 6 mg plus TOCAS 
0.4 mg was associated with a gain of 0.003 QALYs at an additional cost of € 25 per 
patient. The resulting incremental cost effectiveness ratio (ICER) was € 8,471 per 
QALY gained. Time horizon, discontinuation or withdrawal rates and utility values 
were the main drivers of cost-effectiveness. The probability of FDC solifenacin 6 
mg plus TOCAS being cost-effective relative to tolterodine plus tamsulosin was 
97.3% at a willingness to pay threshold of € 30,000 per QALY. cOnclusiOns: The 
FDC of solifenacin 6 mg plus TOCAS is a cost-effective treatment strategy com-
pared with tolterodine plus tamsulosin for men with storage and voiding LUTS/
BPH in the Spanish NHS.
